Yang Li Sells 843 Shares of Surrozen, Inc. (NASDAQ:SRZN) Stock

Surrozen, Inc. (NASDAQ:SRZN) VP Yang Li sold 843 shares of the company’s stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $17.37, for a total value of $14,642.91. Following the completion of the transaction, the vice president now owns 13,345 shares in the company, valued at approximately $231,802.65. The trade was a 5.94 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Surrozen Trading Down 9.0 %

Shares of NASDAQ:SRZN opened at $12.95 on Wednesday. The company has a 50-day moving average price of $11.08 and a two-hundred day moving average price of $9.95. Surrozen, Inc. has a twelve month low of $6.00 and a twelve month high of $18.17.

Surrozen (NASDAQ:SRZN) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($2.77) by $2.33. The business had revenue of $10.00 million for the quarter. As a group, sell-side analysts anticipate that Surrozen, Inc. will post -7.16 EPS for the current fiscal year.

Hedge Funds Weigh In On Surrozen

A number of large investors have recently made changes to their positions in the stock. Armistice Capital LLC bought a new stake in shares of Surrozen during the 2nd quarter valued at $2,080,000. CVI Holdings LLC purchased a new position in Surrozen during the 2nd quarter valued at about $711,000. Nantahala Capital Management LLC bought a new stake in shares of Surrozen during the second quarter valued at about $2,050,000. Finally, Stonepine Capital Management LLC purchased a new stake in shares of Surrozen in the second quarter worth about $724,000. 66.57% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Guggenheim raised Surrozen from a “neutral” rating to a “buy” rating and set a $45.00 price target on the stock in a research report on Friday, January 3rd.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.